Durvalumab (anti-PD-L1) is approved as a maintenance therapy in patients with unresectable, stage 3 NSCLC whose disease has not progressed following concurrent platinum-based chemoradiotherapy (15). The gene discussed is CD274; the disease is non-small cell lung carcinoma.